|
|
|
| The Influence of Bevacizumab Combined with Conventional Treatment on the Levels of Serum IGF-1 and GFAP in Patients with Distant Recurrence of Glioma |
| YUAN Xing, WANG Naibing |
| Department of Neurosurgery,Xi'an International Medical Center Hospital, Xi'an Shaanxi 710100 |
|
|
|
|
Abstract 【Objective】 To investigate the effect of bevacizumab combined with conventional treatment on the levels of serum insulin growth factor-1 (IGF-1) and glial fibrillary acidic protein (GFAP) in patients with distant recurrence of glioma. 【Methods】A total of 78 patients with distant recurrence of glioma admitted to our hospital from January 2020 to January 2024 were selected and divided into the control group (treated with conventional therapy) and the observation group (treated with bevacizumab combined with conventional therapy) by the random number table method, with 39 cases in each group. The short-term therapeutic effects and long-term survival rates of the two groups of patients were compared. The levels of serum IGF-1 and GFAP before and after treatment, as well as the scores of the Stroke Scale (NIHSS) and the Quality of Life Scale for Cancer Patients (EORTIC QLQ-C30) of the two groups of patients were also compared. 【Results】The total effective rate of the observation group was significantly higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, the expression levels of serum IGF-1 and GFAP in both groups were lower than those before treatment, and those in the observation group were lower than those in the control group, with statistically significant differences (P<0.05). After 1 month and 3 months of treatment, the NIHSS scores of both groups were lower than those before treatment, and the scores of the observation group were lower than those of the control group. The difference was statistically significant (P<0.05). The EORTIC QLQ-C30 scores of the two groups of patients were higher than those before treatment, and the observation group was higher than the control group. The difference was statistically significant (P<0.05). The 2-year and 3-year survival rates of patients in the observation group were higher than those in the control group, and the difference was statistically significant (P<0.05). 【Conclusion】 Bevacizumab combined with conventional treatment can significantly improve the long-term survival rate of patients with distant recurrence of glioma, with good clinical efficacy. It can improve the neurological function of patients and enhance their quality of life.
|
|
Received: 26 September 2023
|
|
|
|
|
|
[1] 查昳琳,徐晓婷. 多模态MRI在高级别脑胶质瘤放疗中的应用[J].中华放射肿瘤学杂志,2019,28(3):226-229.
[2] 赵维维,孙静,诸静其. 人工智能在脑胶质瘤MRI诊断中的研究进展[J].磁共振成像,2021,12(8):88-90.
[3] 张真,崔海忠. 替莫唑胺联合放射治疗复发性恶性脑胶质瘤的临床疗效[J].实用癌症杂志,2018,33(2):211-213.
[4] 邹亚,钟萍,罗楠,等. 贝伐珠单抗联合多西他赛及吉西他滨治疗复发性铂类耐药晚期卵巢癌临床效果及随访1年预后[J].中国计划生育学杂志,2023,31(3):547-551.
[5] 覃川,黎成禄,谢惠,等.胶质瘤患者血清 IGF-1 的表达及临床意义[J].重庆医学,2009,38(15):1941-1942.
[6] RESTREPO A,SMITHC A,AGNIHOTRI S,et al .Epi-genetic regulation of glial fibrillary acidic protein by DNA methylation in human malignant gliomas[J].Neuro Oncol,2011,13(1):42-50.
[7] 《中国中枢神经系统胶质瘤诊断和治疗指南》编写组. 中国中枢神经系统胶质瘤诊断与治疗指南(2015)[J].中华医学杂志,2016(7):485-509.
[8] 李康,赵鑫. 脑胶质瘤患者显微手术治疗疗效及预后影响因素[J].中国肿瘤临床与康复,2019,26(4):450-453.
[9] 严亿军,杜战锋,曾海燕,等. 脑胶质瘤术后放化疗复发再手术患者预后的影响因素分析[J].癌症进展,2023,21(4):414-416.
[10] 邹亚,钟萍,罗楠,等. 贝伐珠单抗联合多西他赛及吉西他滨治疗复发性铂类耐药晚期卵巢癌临床效果及随访1年预后[J].中国计划生育学杂志,2023,31(3):547-551.
[11] 杨光霞,程云涛,刘琳琳,等. 阿美替尼片联合贝伐珠单抗注射液治疗表皮生长因子受体突变的晚期非小细胞肺癌患者的临床研究[J].中国临床药理学杂志,2023,39(11):1528-1532.
[12] 刘文鹏,曹经琳,赵鑫,等. ACTR调控IGF-1R对肝癌细胞生长的影响[J].河北医药,2023,45(13):1955-1959.
[13] 任聪聪,张立涛,康进生,等. 血清NSE、CA15-3、S100B、IGF-1在脑胶质瘤中的表达及诊断效能分析[J].解放军医药杂志,2022,34(1):25-28.
[14] 王晶,刘敏,白香花,等. 不同PEEP水平对老年腹腔镜大肠癌患者脑氧饱和度和血清GFAP、NSE的影响[J].内蒙古医科大学学报,2022,44(3):284-287.
[15] 程钰,李永来,黄璐. 高级别脑胶质瘤中GFAP、p53、Ki67的表达水平及临床意义[J].海南医学,2022,33(23):3081-3085. |
|
|
|
2025, Vol. 42 
